DUBLIN–(BUSINESS WIRE)–The “Ophthalmology Drugs Global Market Opportunities and Strategies to 2030: COVID-19 Impact and Recovery” report has been added to ResearchAndMarkets.com’s offering.
This report provides the strategists, marketers and senior management with the critical information they need to assess the global ophthalmology drugs market as it emerges from the COVID-19 shut down.
The global ophthalmology drugs market is expected to decline from $24,640.0 million in 2019 to $19,831.3 million in 2020 at a compound annual growth rate (CAGR) of -19.5%. The decline is mainly due to economic slowdown across countries owing to the COVID-19 outbreak and the measures to contain it. The market is then expected to recover and grow at a CAGR of 44.6% from 2021 and reach $33,272.8 million in 2023. The market is expected to grow at a CAGR of 7.2% to nearly $38,223.53 million by 2025, and at a CAGR of 7.0% to $53,698.87 million by 2030.
Reasons to Purchase
- Outperform competitors using accurate up to date demand-side dynamics information.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
- Create regional and country strategies on the basis of local data and analysis.
- Stay abreast of the latest customer and market research findings
- Benchmark performance against key competitors.
- Develop strategies based on likely future developments.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Gain a global perspective on the development of the market.
This report describes and evaluates the global ophthalmology drugs market. It covers 2015 to 2019, termed the historic period, and 2019 to 2023 termed the forecast period, along with further forecasts for the periods 2023-2025 and 2025-2030.
North America was the largest region in the global ophthalmology drugs market, accounting for 41.4% of the total in 2019. It was followed by Asia-Pacific, Western Europe, South America, and then the other regions. Going forward, the fastest-growing regions in the ophthalmology drugs market will be North America and the Asia Pacific, where growth will be at CAGRs of 8.9% and 8.5% respectively. These will be followed by the Middle East, Africa where the markets are expected to grow at CAGRs of 7.0% and 6.9% respectively.
The ophthalmology drugs market is highly concentrated, with a small number of large players. The top ten competitors in the market made up to 88.0% of the total market in 2019. Major players in the market include Novartis AG, Regeneron Pharmaceuticals Inc., Allergan Plc., Bayer AG, and Santen Pharmaceutical Co. Ltd.
The global pharmaceutical drugs market, of which the ophthalmology drugs market is a segment, reached a value of nearly $936.3 billion in 2019, having grown at a CAGR of 3.9% since 2015. It is expected to grow at a CAGR of 8.5% to nearly $1,298.6 billion by 2023. The ophthalmology drugs market was the smallest segment of the pharmaceutical drugs market accounting for 2.6% of the total in 2019. The dermatology drugs segment is expected to be the fastest-growing segment in the pharmaceutical drugs market, growing at a CAGR of 13.0% during 2019-2023.
The outbreak of Coronavirus has caused a shortage in the supply of ophthalmic drugs for the treatment of dry eyes. This is because the COVID-19 pandemic created disruption in the global pharmaceutical supply chain which is heavily dependent on China. The main raw materials in drug production are manufactured in China and are exported to other parts of the world for making the final drug. This has resulted in pharmacies and wholesalers reporting many drugs being out of stock.
Key Topics Covered:
1. Ophthalmology Drugs Market Executive Summary
2. Table of Contents
3. List of Figures
4. List of Tables
5. Report Structure
6. Introduction
7. Ophthalmology Drugs Market Characteristics
8. Ophthalmology Drugs Market Product Analysis – Product Examples
9. Ophthalmology Drugs Market Supply Chain Analysis
10. Ophthalmology Drugs Market Customer Information
11. Ophthalmology Drugs Market Trends And Strategies
12. Leading Ophthalmologic Drug Therapies
13. Gene Therapy In Ophthalmology
14. Unmet Needs In Ophthalmology Drugs Market
15. Impact of COVID-19 On Ophthalmology Drugs Market
16. Global Ophthalmology Drugs Market Size And Growth
17. Ophthalmology Drugs Market, Regional Analysis
18. Global Ophthalmology Drugs Market Segmentation
19. Global Ophthalmology Drugs Market Comparison with Macro Economic Factors
Companies Mentioned
- Adcock Ingram
- Aflofarm Farmacja Polska Sp. z o. o,
- Akron Inc.
- Alcon Pharmaceuticals Czech Republic S.r.o.
- Aurinia Pharmaceuticals Inc
- Bausch Health Companies Inc.
- Biolab Farmaceutica
- Cristalia
- Daiichi Sankyo
- Endo International plc
- ERC Labs
- F. Hoffmann-La Roche Ltd.
- Herzig Eye Institute
- Implandata ophthalmic products GmbH
- Johnson & Johnson
- Medicom Health care
- Novamedika
- Otsuka Pharmaceutical Co. Ltd
- Pfizer Inc.
- Regenerx Biopharmaceuticals Inc
- ReGenTree, LLC
- Shanghai Pharmaceuticals
- Shire
- Sun Pharmaceutical Industries Limited
- Teuto Brasileiro
- The Geuder Group, MORCHER GmbH
- Thomas Eye Group
- Vision gain
- VUAB Pharma, Inc
For more information about this report visit https://www.researchandmarkets.com/r/ur5gd6
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900